



## Herbal Medicine for the Treatment of Fatty Liver Disease

Guest Editors:

**Dr. Hsing-Yu Chen**

Graduate Institute of Clinical  
Medical Sciences, College of  
Medicine, Chang Gung University,  
Taoyuan 333, Taiwan

**Dr. Chao-Wei Lee**

Division of General Surgery,  
Département of Surgery, Linkou  
Chang Gung Memorial Hospital,  
Taoyuan City, Taiwan

Deadline for manuscript  
submissions:

**closed (31 May 2023)**

### Message from the Guest Editors

Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder. As a chronic disease with heterogeneous etiologies, complicated pathogenesis, and multiple co-morbidities, NAFLD may progress to non-alcoholic steatohepatitis (NASH) and even cirrhosis if it cannot be managed appropriately. However, the medical therapies for NAFLD are still limited. Therefore, new agents with or without non-pharmacological treatments are still needed.

Herbal medicine (HM) has been used in many countries for thousands of years. Several HMs have anti-NAFLD effects through modulating lipid metabolisms, oxidative stress, autophagy, and other mechanisms. Resveratrol has been reported to have the ability to enhance autophagy and reduce oxidative stress and fibrosis. On the other hand, management of the NAFLD-related co-morbidities is also essential to deal with NAFLD.

The purpose of this Special Issue is to investigate the feasibility of HM in managing NAFLD. Clinical, in vitro, or in vivo studies are all welcome for submission to this Special Issue.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)